Carl L. Gordon, a director at Scribe Therapeutics, Inc. (SCTX), disclosed an open-market purchase of 1,000,000 shares at $15.00 per share, a bet worth exactly $15,000,000.00, according to a Form 4 filed with the SEC. The transaction is dated July 27, 2026.
Following the purchase, Gordon’s stake stands at 1,348,825 shares, held indirectly through a trust or entity structure rather than in his own name. That detail matters to filing-watchers because indirect ownership often signals shares held through an investment vehicle tied to the director’s broader role at the company, rather than a simple personal brokerage account.
This was not a grant of options or a routine vesting event — Gordon spent his own money on the open market to acquire the stake, which is the kind of signal that tends to draw attention among readers searching for the largest insider buys this week. Open-market purchases by directors are generally viewed differently than automatic transactions like 10b5-1 plan sales or option exercises, since they require the insider to commit personal capital at the prevailing market price.
A Notable Coincidence in Timing
Gordon’s purchase landed on the same date as another eight-figure insider buy at Scribe Therapeutics. An OrbiMed-affiliated director also purchased $15M in SCTX shares on July 27, 2026, a filing covered separately at SCTX Insider Buy: OrbiMed Director Buys $15M in Shares. Two directors independently committing identical dollar amounts on the same trading day is an unusual data point worth noting for anyone tracking clustered activity at the company.
Academic research on insider trading disclosures has found that clustered buying — multiple insiders purchasing shares independently within a short window — can correlate with subsequent outperformance on average, though any individual filing is just one data point and this disclosure should not be read as a signal to act on. The filing itself does not explain Gordon’s rationale, and SEC disclosures rarely do.
What the record shows plainly is the mechanics: a director, a market purchase, a seven-figure share count, and a resulting position of nearly 1.35 million shares held indirectly. Readers interested in the fuller pattern of insider activity around Scribe Therapeutics this week can also review the earlier disclosure from AH Bio Fund II, which detailed a separate $5 million purchase around the same period.
Source: original SEC Form 4 filing.